The CGRP receptor antagonists include erenumab, ubrogepant, rimegepant, and atogepant as receptor targets. This category is best described as:

The CGRP receptor antagonists include erenumab, ubrogepant, rimegepant, and atogepant as receptor targets. This category is best described as:

• A. Ligand-targeting antibodies
• B. Receptor-targeting antagonists
• C. Serotonin reuptake inhibitors
• D. Vasodilators

Answer: (B)

The drugs described work by blocking the CGRP signaling pathway at the receptor, not by targeting the CGRP ligand itself. Erenumab is a monoclonal antibody that binds to the CGRP receptor, while ubrogepant, rimegepant, and atogepant are small-molecule antagonists that bind the same receptor and prevent CGRP from activating it. By occupying the receptor, they stop CGRP-induced vasodilation and nociceptive signaling that contribute to migraine. This makes the category best described as receptor-targeting antagonists. Ligand-targeting antibodies would target the CGRP peptide itself, which is not the common mechanism here. Serotonin reuptake inhibitors and direct vasodilators don’t describe this mechanism either, since the key feature is blocking receptor activation rather than altering serotonin transport or promoting dilation.

The drugs described work by blocking the CGRP signaling pathway at the receptor, not by targeting the CGRP ligand itself. Erenumab is a monoclonal antibody that binds to the CGRP receptor, while ubrogepant, rimegepant, and atogepant are small-molecule antagonists that bind the same receptor and prevent CGRP from activating it. By occupying the receptor, they stop CGRP-induced vasodilation and nociceptive signaling that contribute to migraine. This makes the category best described as receptor-targeting antagonists.

Ligand-targeting antibodies would target the CGRP peptide itself, which is not the common mechanism here. Serotonin reuptake inhibitors and direct vasodilators don’t describe this mechanism either, since the key feature is blocking receptor activation rather than altering serotonin transport or promoting dilation.